Last reviewed · How we verify
Bryhali
Bryhali is a Small molecule drug developed by Icahn School of Medicine at Mount Sinai. It is currently in discontinued development. Also known as: halobetasol propionate.
At a glance
| Generic name | Bryhali |
|---|---|
| Also known as | halobetasol propionate |
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- NCT01166646 (Phase 2)
- An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily Halobetasol Propionate Lotion, 0.05% in Subjects 12 to 16 Years 11 Months of Age With Plaque (Phase 4)
- Bioequivalence of Three Halobetasol Propionate 0.05% Topical Creams (N/A)
- Investigator-Initiated, Open Label Trial of a Combination of Halobetasol Propionate 0.01% Andtazarotene 0.045% Lotion (Duobrii®) for Plaque Type Psoriasis of the Hands and/or Feet (Phase 4)
- An Open-label Safety Study to Assess the Multiple-dose Pharmacokinetics and Potential for Adrenal Suppression Following Topical Treatment With Halobetasol Propionate 0.05% Topical Spray Applied Twice (Phase 2)
- Clinical Trial of Effectiveness and Safety of Topical Halobetasol Propionate in the Treatment of Patients With Psoriasis Plate, and as Comparator the Product Psorex (Clobetasol Propionate). (Phase 2)
- Bioequivalence of Two Halobetasol Propionate 0.05% Topical Ointments (N/A)
- A Demonstration of the Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion as Compared to 0.05% Clobetasol Propionate Cream in the Treatment of Psoriasis (Phase 4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bryhali CI brief — competitive landscape report
- Bryhali updates RSS · CI watch RSS
- Icahn School of Medicine at Mount Sinai portfolio CI
Frequently asked questions about Bryhali
What is Bryhali?
Bryhali is a Small molecule drug developed by Icahn School of Medicine at Mount Sinai.
Who makes Bryhali?
Bryhali is developed by Icahn School of Medicine at Mount Sinai (see full Icahn School of Medicine at Mount Sinai pipeline at /company/icahn-school-of-medicine-at-mount-sinai).
Is Bryhali also known as anything else?
Bryhali is also known as halobetasol propionate.
What development phase is Bryhali in?
Bryhali is in discontinued.
Related
- Manufacturer: Icahn School of Medicine at Mount Sinai — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: halobetasol propionate
- Compare: Bryhali vs similar drugs
- Pricing: Bryhali cost, discount & access